Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Nov 24:359:j5157.
doi: 10.1136/bmj.j5157.

Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU)

Andrew Jull  1   2 , Angela Wadham  2 , Chris Bullen  2 , Varsha Parag  2 , Ngaire Kerse  3 , Jill Waters  4
Affiliations
Randomized Controlled Trial

Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU)

Andrew Jull et al. BMJ. .

Abstract

Objective To determine the effect of low dose aspirin on ulcer healing in patients with venous leg ulcers.Design Pragmatic, community based, parallel group, double blind, randomised controlled trial.Setting Five community nursing centres in New Zealand.Participants 251 adults with venous leg ulcers who could safely be treated with aspirin or placebo: 125 were randomised to aspirin and 126 to placebo.Interventions 150 mg oral aspirin daily or matching placebo for up to 24 weeks treatment, with compression therapy as standard background treatment.Main outcome measures The primary outcome was time to complete healing of the reference ulcer (largest ulcer if more than one ulcer was present). Secondary outcomes included proportion of participants healed, change in ulcer area, change in health related quality of life, and adverse events. Analysis was by intention to treat.Results The median number of days to healing of the reference ulcer was 77 in the aspirin group and 69 in the placebo group (hazard ratio 0.85, 95% confidence interval 0.64 to 1.13, P=0.25). The number of participants healed at the endpoint was 88 (70%) in the aspirin group and 101 (80%) in the placebo group (risk difference -9.8%, 95% confidence interval -20.4% to 0.9%, P=0.07). Estimated change in ulcer area was 4.1 cm2 in the aspirin group and 4.8 cm2 in the placebo group (mean difference -0.7 cm2, 95% confidence interval -1.9 to 0.5 cm2, P=0.25). 40 adverse events occurred among 29 participants in the aspirin group and 37 adverse events among 27 participants in the placebo group (incidence rate ratio 1.1, 95% confidence interval 0.7 to 1.7, P=0.71).Conclusion Our findings do not support the use of low dose aspirin as adjuvant treatment for venous leg ulcers.Trial registration ClinicalTrials.gov NCT02158806.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; the HRC of New Zealand funded this trial; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Participant flow diagram. All people screened were patients with venous leg ulcers. Information on healing status (and date of healing if appropriate) for the primary outcome analysis on all participants lost to follow-up were obtained from the participants’ clinical records at the last point of contact
None
Fig 2 Kaplan-Meier plot for time to complete healing of venous leg ulcer by trial treatment group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Petherick ES, Pickett KE, Cullum NA. Can different primary care databases produce comparable estimates of burden of disease: results of a study exploring venous leg ulceration. Fam Pract 2015;32:374-80.pmid:25934977. - PMC - PubMed
    1. Iglesias C, Nelson EA, Cullum NA, Torgerson DJ. VenUS Team. VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technol Assess 2004;8:iii , 1-105. 10.3310/hta8290 pmid:15248939. - DOI - PubMed
    1. Jull A, Walker N, Parag V, Molan P, Rodgers A. Honey as Adjuvant Leg Ulcer Therapy trial collaborators. Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. Br J Surg 2008;95:175-82. 10.1002/bjs.6059 pmid:18161896. - DOI - PubMed
    1. O’Donnell TF Jr, , Passman MA, Marston WA, et al. Society for Vascular Surgery American Venous Forum. Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery ® and the American Venous Forum. J Vasc Surg 2014;60(Suppl):3S-59S. 10.1016/j.jvs.2014.04.049 pmid:24974070. - DOI - PubMed
    1. Jull A, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2007;(3):CD001733.pmid:17636683. - PubMed

Publication types

Associated data